中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners




Linkedbio Report No.170

In this month summary, Lingmed recommends

  • Assets recommendation-TCR-T
  • The June Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team


Linkedbio Report No.168

Lingmed recommends

LMC5000489 is a world-class Immuno-oncology company focused on living Immunotherapies, harness the power of living T cells to engage the body’s own immune system to fight cancer. Currently it is seeking strategic cooperation partner in China for the further development of its novel technology platform “T-cell receptor-modified T cells (TCRs) ”.  Lingmed Medicals was authorized as its exclusive agent in China for this project
T-cell receptor modified T cell therapy (TCR-T) provides autologous or allogeneic T cells that are genetically engineered with tumor specifc TCR α β chain and constitutes a promising approach of adoptive cellular immunotherapy for the treatment of tumors. The current challenge of TCR gene therapy is the acquisition of tumor-specific high-affinity TCR gene and the optimization of TCR α and β transgene pairing to enhance the functional avidity of therapeutic T cells




If you are interested in Lingmed historical achieved reports, please click here





Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

©Copyright 2013 - 2018 Lingmed Limited